Table 2 Basic demographics of the patients
All | Risk model n = 109 n (%) | Low-risk n = 76 n (%) | High-risk n = 33 n (%) | P value | |
|---|---|---|---|---|---|
n = 158 | Low vs. | ||||
n (%) | high risk | ||||
Sex | 0.302 | ||||
Male | 108 (68.4%) | 75 (68.8%) | 50 (65.8%) | 25 (75.8%) | |
Female | 50 (31.6%) | 34 (31.2%) | 26 (34.2%) | 8 (24.2%) | |
Age | 0.923 | ||||
≤ 65 years | 76 (48.1%) | 47 (43.1%) | 33 (43.4%) | 14 (42.4%) | |
> 65 years | 82 (51.9%) | 62 (56.9%) | 43 (56.6%) | 19 (57.6%) | |
PS (WHO) | 0.003* | ||||
0 | 92 (58.2%) | 66 (60.6%) | 53 (69.7%) | 13 (39.4%) | |
≥ 1 | 66 (41.8%) | 43 (39.4%) | 23 (30.3%) | 20 (60.6%) | |
Cancer type | 0.288 | ||||
NSCLC | 75 (47.5%) | 52 (47.7%) | 37 (48.7%) | 15 (45.5%) | |
Melanoma | 28 (17.7%) | 19 (17.4%) | 16 (21.1%) | 3 (9.1%) | |
RCC | 26 (16.5%) | 19 (17.4%) | 10 (13.2%) | 9 (27.3%) | |
Head and neck | 8 (5.1%) | 7 (6.4%) | 3 (3.9%) | 4 (12.1%) | |
MSI high | 7 (4.4%) | 5 (4.6%) | 4 (5.3%) | 1 (3.0%) | |
Urothelial | 8 (5.1%) | 4 (3.7%) | 3 (3.9%) | 1 (3.0%) | |
Lymphoma | 5 (3.2%) | 2 (1.8%) | 2 (2.6%) | 0 (0%) | |
TNBC | 1 (0.6%) | 1 (0.9%) | 1 (1.3%) | 0 (0%) | |
Metastatic sites | |||||
Lymph nodes | 104 (65.8%) | 71 (65.1%) | 46 (60.5%) | 25 (75.8%) | 0.125 |
Lung | 89 (56.3%) | 60 (55.0%) | 44 (57.9%) | 16 (48.5%) | 0.364 |
Bone | 47 (29.7%) | 33 (30.3%) | 17 (22.4%) | 16 (48.5%) | 0.006* |
Liver | 33 (20.9%) | 27 (24.8%) | 16 (21.1%) | 11 (33.3%) | 0.172 |
Brain | 17 (10.8%) | 12 (11.0%) | 8 (10.5%) | 4 (12.1%) | 0.752 |